Iovance Biotherapeutics Inc (IOVA)
10.01
-0.25
(-2.44%)
USD |
NASDAQ |
May 24, 16:00
10.06
+0.05
(+0.50%)
After-Hours: 20:00
Iovance Biotherapeutics Cash from Financing (Quarterly): 193.58M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 193.58M |
| December 31, 2023 | 0.962M |
| September 30, 2023 | 202.80M |
| June 30, 2023 | 1.025M |
| March 31, 2023 | 258.17M |
| December 31, 2022 | 190.58M |
| September 30, 2022 | 0.225M |
| June 30, 2022 | -2.067M |
| March 31, 2022 | 1.417M |
| December 31, 2021 | 4.15M |
| September 30, 2021 | 20.77M |
| June 30, 2021 | 163.98M |
| March 31, 2021 | 50.36M |
| December 31, 2020 | 2.958M |
| September 30, 2020 | 1.166M |
| June 30, 2020 | 568.46M |
| March 31, 2020 | 3.833M |
| December 31, 2019 | 2.088M |
| September 30, 2019 | 0.664M |
| June 30, 2019 | 3.381M |
| March 31, 2019 | -0.002M |
| December 31, 2018 | 239.34M |
| September 30, 2018 | 12.02M |
| June 30, 2018 | 3.36M |
| March 31, 2018 | 169.58M |
| Date | Value |
|---|---|
| December 31, 2017 | 2.899M |
| September 30, 2017 | 56.05M |
| June 30, 2017 | -0.648M |
| March 31, 2017 | 0.383M |
| December 31, 2016 | 0.216M |
| September 30, 2016 | 0.494M |
| June 30, 2016 | 96.19M |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.275M |
| September 30, 2015 | 1.709M |
| June 30, 2015 | 5.671M |
| March 31, 2015 | 70.61M |
| December 31, 2014 | 32.46M |
| September 30, 2014 | 0.6385M |
| June 30, 2014 | 1.821M |
| March 31, 2014 | 0.5425M |
| December 31, 2013 | 21.79M |
| September 30, 2013 | 0.00 |
| June 30, 2013 | 1.252M |
| March 31, 2013 | 0.30M |
| December 31, 2012 | 0.00 |
| September 30, 2012 | 0.265M |
| June 30, 2012 | 1.216M |
| March 31, 2012 | 0.25M |
| December 31, 2011 | 2.37M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-2.067M
Minimum
Jun 2022
568.46M
Maximum
Jun 2020
83.43M
Average
3.607M
Median
Cash from Financing (Quarterly) Benchmarks
| Viatris Inc | -425.60M |
| Perspective Therapeutics Inc | 166.33M |
| Electromed Inc | 0.056M |
| Xtant Medical Holdings Inc | 5.179M |
| Asensus Surgical Inc | 0.811M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -122.28M |
| Cash from Investing (Quarterly) | -111.51M |
| Free Cash Flow | -405.08M |
| Free Cash Flow Per Share (Quarterly) | -0.475 |
| Free Cash Flow to Equity (Quarterly) | -126.45M |
| Free Cash Flow to Firm (Quarterly) | -126.45M |
| Free Cash Flow Yield | -16.31% |